Track Penumbra, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Penumbra, Inc. PEN Open Penumbra, Inc. in new tab

326.55 USD
P/E
74.36
EPS
4.33
P/B
8.85
ROE
12.73
Beta
0.74
Target Price
363.36 USD
Penumbra, Inc. logo

Penumbra, Inc.

🧾 Earnings Recap – Q3 2025

Penumbra reported strong third-quarter results for 2025, achieving $354.7 million in revenue driven by robust growth across its U.S. thrombectomy and embolization franchises, highlighting its competitive positioning and successful product innovation.

  • Total revenue increased by 17.8% year-over-year, with U.S. revenue growing 21.5% to $275 million.
  • The VTE franchise achieved remarkable 34% year-over-year growth, affirming its market leadership.
  • Gross margin expanded to 67.8%, with operating income at $48.8 million (13.8% of revenue), and future margins are projected to exceed 70%.
  • FDA clearance for breakthrough products Lightning Bolt 16 and Lightning Flash 3.0 enhances Penumbra's advanced CAVT device portfolio.
  • The integration of a dedicated embolization sales team has resulted in a 21.2% sequential revenue increase in this segment.
📅
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateAug. 4, 2026
P/E74.36
EPS4.33
Book Value36.39
Price to Book8.85
Debt/Equity14.67
% Insiders2.922%
Growth
Revenue Growth0.16%
Earnings Growth-0.18%
Estimates
Forward P/E51.13
Forward EPS6.30
Target Mean Price363.36

DCF Valuation

Tweak assumptions to recompute fair value for Penumbra, Inc. (PEN)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Penumbra, Inc. Logo Penumbra, Inc. Analysis (PEN)

United States Health Care Official Website Stock

Is Penumbra, Inc. a good investment? Penumbra, Inc. (PEN) is currently trading at 326.55 USD. Market analysts have a consensus price target of 363.36 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 74.36. This high multiple suggests investors have priced in significant future growth expectations.

Earnings Schedule: Penumbra, Inc. is expected to release its next earnings report on Aug. 4, 2026. The market consensus estimate for Forward EPS is 6.30.

Investor FAQ

Does Penumbra, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Penumbra, Inc.?

Penumbra, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Aug. 4, 2026. The company currently has a trailing EPS of 4.33.

Company Profile

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.

Exchange Ticker
NYQ (United States) PEN

Dividends

Historical Split Corporate Actions

Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion